Clinical trials: sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Generalized Pustular Psoriasis
A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study, all subjects need to use TQH2929 injection/placebo.
- Trial name
- NCT07314060
- Testing
- TQH2929 Injections
- Where
- 31 sites in China
- Volunteers
- 36 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Solid Tumors
Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid Tumors
This is a multicenter phase II study designed to evaluate the efficacy and safety of TQB3454 as monotherapy in patients with advanced solid tumors, divided into three cohorts.Cohort 1: Enrolled patients with diffuse glioma…
- Trial name
- NCT07738679
- Testing
- TQB3454 tablets
- Where
- 22 sites in China
- Volunteers
- 127 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cancers
A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
TQB3107 is an target inhibitor that binds to target to induce apoptosis and inhibits the proliferation of a variety of tumor cells.
- Trial name
- NCT06413953
- Testing
- TQB3107 Tablets
- Where
- 12 sites in China
- Volunteers
- 140 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Myelofibrosis
Study to Evaluate the Effect of Rabeprazole Sodium Enteric-coated Tablets on the Pharmacokinetics of TQ05105 Tablets
Primary objective: To evaluate the effect of rabeprazole on the primary pharmacokinetics of TQ05105 tablets. Secondary objective: To assess the safety and tolerability of single oral administration of TQ05105 tablets alone and in…
- Trial name
- NCT07608666
- Testing
- TQ05105 tablets, Rabeprazole sodium enteric-coated tablets
- Where
- China
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Myelofibrosis
A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis
This is an open-label, single-arm, multi-center phase II study consisting of two cohorts. Cohort 1 evaluates the pharmacokinetics (PK) of TQ05105 in myelofibrosis participants with normal, mild, or moderate renal impairment to…
- Trial name
- NCT07551427
- Testing
- TQ05105 Tablets (Rovadicitinib Tablets)
- Where
- 24 sites in China
- Volunteers
- 51 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Adult Non-infectious Uveitis
A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis
This study is a real-world clinical research on adalimumab. The project plans to enroll 30 subjects. The safety and efficacy of adalimumab injection for adult non-infectious uveitis are being investigated.
- Trial name
- NCT07663331
- Testing
- TyboWe® Adalimumab Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Systemic Lupus Erythematosus
A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus
To assess the efficacy and safety of TQH3906 in treating systemic lupus erythematosus.
- Trial name
- NCT07509892
- Testing
- TQH3906 capsule
- Where
- 35 sites in China
- Volunteers
- 198 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Malignant Tumors
To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant Tumors
To explore the safety, tolerability and pharmacokinetics of TQB3142 for injection in subjects with advanced malignant tumors
- Trial name
- NCT07338838
- Testing
- TQB3142 injection
- Where
- 5 sites in China
- Volunteers
- 66 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pulmonary Disease, Chronic Obstructive
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder
To evaluate the efficacy and safety of TQC3721 inhalation powder in patients with moderate to severe Chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT07252908
- Testing
- TQC3721 inhalation powder
- Where
- 29 sites in China
- Volunteers
- 195 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Myeloproliferative Neoplasms
A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms
TQ05105 is a JAK2 inhibitors and can be used to treat JAK2 target-related diseases. The activation of the JAK/STAT pathway is related to abnormal proliferation, obstruction of apoptosis, and differentiation disorder of leukemia…
- Trial name
- NCT04339400
- Testing
- TQ05105
- Where
- 2 sites in China
- Volunteers
- 79 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Glucocorticoid-Refractory aGVHD
A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)
This is an open-label,single arm,Phase Ib study,in order to evaluate the safety,tolerability, preliminary efficacy and pharmacokinetics of TQ05105 tablets in subjects with Glucocorticoid-Refractory aGVHD
- Trial name
- NCT04941404
- Testing
- TQ05105 tablets
- Where
- 4 sites in China
- Volunteers
- 13 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Moderate and High Risk Myelofibrosis
A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
Q05105 tablet is a Janus kinase 2 (JAK2) inhibitor, which can be used to treat JAK2 target related diseases, such as moderate or high-risk multiple myelofibrosis
- Trial name
- NCT05020652
- Testing
- TQ05105 tablets, Hydroxycarbamide tablets
- Where
- 4 sites in China
- Volunteers
- 107 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Plexiform Neurofibroma
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
This study aims to demonstrate that in subjects with symptomatic, inoperable plexiform neurofibromas associated with neurofibromatosis type 1, TQ-B3234 capsules significantly improve the objective response rate at Week 24…
- Trial name
- NCT07407803
- Testing
- TQ-B3234 capsules
- Where
- 29 sites in China
- Volunteers
- 177 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Multiple Myeloma
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
This study is a randomized, open-label, multicenter Phase III clinical trial involving patients with relapsed/refractory multiple myeloma.
- Trial name
- NCT07569757
- Testing
- TQB2934 injection, Pomalidomide Capsule, Selinexor tablets
- Where
- 49 sites in China
- Volunteers
- 260 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Extensive Stage Small Cell Lung Cancer
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
This is a randomized, controlled, open-label, multicenter clinical study to evaluate the efficacy and safety of carboplatin/cisplatin + etoposide + benmelstobart sequential benmelstobart combined with anlotinib versus…
- Trial name
- NCT06897579
- Testing
- Carboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsule, Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injection
- Where
- 32 sites in China
- Volunteers
- 40 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Alveolar Soft Part Sarcoma
Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma
This is a Phase II, single-arm, multicenter clinical study aimed at demonstrating the effectiveness of benmelstobart injection combined with anlotinib hydrochloride capsules in patients aged 14 years or older with advanced or…
- Trial name
- NCT07548177
- Testing
- Benmelstobart injection combined with Anlotinib hydrochloride capsule
- Where
- 15 sites in China
- Volunteers
- 33 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Malignant Cancer
Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors
The trial was divided into two phases: dose escalation and dose expansion. The dosing regimens were single-dose study and continuous dosing study.
- Trial name
- NCT07482592
- Testing
- TQB3205 capsules
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Lung Cancer
A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function
Evaluation of the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects with Impaired Liver Function versus Normal Liver Function
- Trial name
- NCT07538973
- Testing
- Anecatibin Fumarate Capsules
- Where
- 3 sites in China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
This is a Phase III, randomized, double-blind, parallel, multi-center trail to evaluate the efficacy and safety of TQB3616 capsule combined with endocrine compared to placebo compared with endocrine in HR-positive and…
- Trial name
- NCT05780567
- Testing
- TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen
- Where
- 3 sites in China
- Volunteers
- 1,946 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Severe Plaque Psoriasis in Chinese Children
A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis
This study is a real-world clinical study of adalimumab. The project plans to enrol 30 participants and aims to evaluate the efficacy and safety of adalimumab in Chinese children with plaque psoriasis, with the primary endpoint…
- Trial name
- NCT07529925
- Testing
- Adalimumab Solution for Injection
- Volunteers
- 30 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.